Boosting a key brain protein could help treat Rett syndrome
Why it matters: This breakthrough offers a potential path to the first effective treatment for Rett syndrome, a devastating neurodevelopmental disorder.
- Texas Children's Hospital and Baylor College of Medicine researchers have identified a new gene-targeting strategy to increase the MeCP2 protein, which is disrupted in Rett syndrome.
- Dr. Huda Zoghbi, director of the Duncan NRI, highlights that Rett syndrome primarily affects girls, causing severe impairments after 6-18 months of normal development.
- Loss of function mutations in the MECP2 gene are responsible for Rett syndrome, leading to missing or dysfunctional MeCP2 protein that regulates other genes vital for neurological processes.
- Experiments in mouse models have shown that introducing healthy MeCP2 protein or increasing levels of partially functional mutant MeCP2 can reverse symptoms and improve survival, movement, and breathing.
- Harini Tirumala notes that approximately 65% of Rett syndrome patients have partially functional MeCP2, making this strategy of boosting mutant protein levels a viable therapeutic concept.
A groundbreaking gene-targeting strategy developed by researchers at Texas Children's Hospital and Baylor College of Medicine shows promise in treating Rett syndrome by boosting a critical brain protein. Early studies in mice and patient-derived cells demonstrate that this approach can restore normal brain cell function, offering hope for future therapies for this rare neurodevelopmental disorder.
